CD226 and breast cancer: One mechanism used by TIGIT to downregulate DNAM-1 is inhibiting DNAM-1 homodimerization, which was demonstrated in colon cancer and breast cancer models [188] and provides a potential, testable DNAM-1 inhibition mechanism in melanoma.